Adcock buys Cosme assets with eye on Indian free medicines plan
This article was originally published in Scrip
South Africa's Adcock Ingram is acquiring certain core assets of the privately-owned Indian firm, Cosme Farma Laboratories, for about Rand778 million ($94.3 million), as part of its strategy to wedge deeper into the fast-growing Indian market. It also appears to have its eye on potential opportunities emerging from India's proposed free medicines plan.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.